spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  cSSSI 

 HSMN NewsFeed - 6 Nov 2018
Cumberland Pharmaceuticals To Acquire VIBATIV(R)
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 23 Apr 2018
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV(R) (telavancin) at 2018 ECCMID(TM) Conference
Biopharmaceuticals
 HSMN NewsFeed - 26 Sep 2016
MicuRx Closes $55 Million Series C Financing to Support Development of Next-Generation Antibiotic MRX-I
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 15 Sep 2016
Teva Strengthens Injectables Portfolio with the Launch of an Authorized Generic of Cubicin(R) (Daptomycin for Injection) in the United States
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 9 May 2016
Theravance Biopharma Announces FDA Approval of Expanded Label for VIBATIV(R) (telavancin)
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 May 2012
Paratek Announces Appointments of Dennis Molnar as Chief Executive Officer and Director and of Dr. Evan Loh as Chief Medical Officer and Chairman of the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Sep 2011
Astellas and Theravance Announce European Marketing Authorization for VIBATIV(R) for Nosocomial Pneumonia Caused by MRSA
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Dec 2010
Cubist Pharmaceuticals Receives FDA Approval for 2-Minute IV Injection of CUBICIN
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Sep 2010
FDA Advisory Committee Recommends Approval of Forest Laboratories' Ceftaroline Fosamil for the Treatment of Community Acquired Bacterial Pneumonia and Complicated Skin and Skin Structure Infections
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Dec 2009
FDA Issues Complete Response Letter for Ceftobiprole
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Dec 2009
Forest Laboratories Announces Acquisition of Additional Rights Related to NXL 104, a Novel Broad-Spectrum Beta-Lactamase Inhibitor
Biopharmaceuticals Licensing
 HSMN NewsFeed - 27 Nov 2009
Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Nov 2009
Theravance and Astellas Announce the Commercial Launch of VIBATIV(TM) (telavancin) in the United States
Biopharmaceuticals
 HSMN NewsFeed - 28 Oct 2009
Nabriva Therapeutics Raises Euro 15 Million (USD 22 Million)
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Oct 2009
Paratek Pharmaceuticals Signs Worldwide License and Commercialization Agreement for PTK 0796, Broad-Spectrum Oral and IV Antibiotic in Phase 3
Biopharmaceuticals Licensing
 HSMN NewsFeed - 1 Oct 2009
Astellas and Theravance Announce Approval of VIBATIV(TM) (telavancin) in Canada for the Treatment of Complicated Skin and Skin Structure Infections
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Aug 2009
Forest Laboratories and AstraZeneca to Co-Develop and Commercialize a Late Stage Next Generation Anti-Infective
Biopharmaceuticals
 HSMN NewsFeed - 24 Mar 2009
FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Jan 2009
FDA Issues Complete Response Letter for Iclaprim
Biopharmaceuticalas FDA
 HSMN NewsFeed - 12 Jan 2009
The Medicines Company to Acquire Targanta Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 Jul 2008
Arpida Submits Marketing Authorisation Application for Intravenous Iclaprim in Europe
Biopharmaceuticals
 HSMN NewsFeed - 30 Jun 2008
Ceftobiprole, a new anti-MRSA broad-spectrum antibiotic, receives its first marketing authorization by Health Canada
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Jun 2008
Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
Biopharmaceuticals
 HSMN NewsFeed - 29 May 2008
Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Apr 2008
Arpida Provides Comprehensive Overview of Pivotal Phase III Trial Data
Biopharmaceuticals
 HSMN NewsFeed - 5 Mar 2008
FDA Accepts for Review Theravance's Complete Response to Approvable Letter for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Feb 2008
Oculus Innovative Sciences Announces Positive Top-Line Phase II Data with Microcyn(R) Technology in Mildly Infected Diabetic Foot Ulcers
Biopharmaceuticals Wound Care
 HSMN NewsFeed - 27 Dec 2007
Theravance Receives Notice of Possible Telavancin Review by FDA Advisory Committee
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Dec 2007
Theravance Announces Positive Topline Results In Phase 3 Telavancin Hospital-Acquired Pneumonia Program
Biopharmaceuticals
 HSMN NewsFeed - 24 Oct 2007
FDA Accepts Wyeth's Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
Biopharmaceuticals
 HSMN NewsFeed - 22 Oct 2007
Theravance Receives FDA Approvable Letter for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Oct 2007
New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections
Biopharmaceuticals Wound Care
 HSMN NewsFeed - 18 Sep 2007
New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
Biopharmaceuticals
 HSMN NewsFeed - 14 Sep 2007
Canadian Regulatory Authority has Accepted for Review New Drug Submission for Ceftobiprole
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Sep 2007
Theravance Retains Full Ownership of Gastrointestinal Motility Dysfunction Program and TD-1792 Antibiotic
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 17 Jul 2007
Basilea Announces Filing of New Drug Submission in Canada for Ceftobiprole
Biopharmaceuticals
 HSMN NewsFeed - 21 Jun 2007
Arpida Receives Approval From US FDA to Initiate a Phase II Trial With iclaprim in Hospital-Acquired, Ventilator and Healthcare-Associated Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Jun 2007
Basilea Announces Submission of Marketing Authorization Application in Europe by Janssen-Cilag International NV for Ceftobiprole, a Novel Anti-MRSA Broad-spectrum Cephalosporin
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 May 2007
Theravance Announces Acceptance of Telavancin MAA for the Treatment of Complicated Skin and Soft Tissue Infections in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 May 2007
New Drug Application Submitted For Novel Investigational Antibiotic Ceftobiprole
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 May 2007
Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Complicated Skin and Soft Tissue Infections in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Feb 2007
Theravance Announces FDA Acceptance of Telavancin NDA
Biopharmaceuticals
 HSMN NewsFeed - 9 Feb 2007
Targanta Announces $70 Million Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 10 Jan 2007
Basilea Announces Positive Top-Line Results On Second Pivotal Phase III Ceftobiprole Trial
Biopharmaceuticals
 HSMN NewsFeed - 14 Dec 2006
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Dec 2006
Forest Laboratories Announces Acquisition of Cerexa, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 10 Oct 2006
Theravance Announces Additional Results From Successful Phase 3 Telavancin Complicated Skin and Skin Structure Program
Biopharmaceuticals
 HSMN NewsFeed - 29 Sep 2006
Efficacy of Once-Daily AVELOX(R) in Treating Complicated Intra-Abdominal Infections Highlighted in Two Clinical Data Presentations at ICAAC
Biopharmaceuticals
 HSMN NewsFeed - 22 Aug 2006
Theravance Announces Positive Results in Phase 3 Telavancin Complicated Skin and Skin Structure Infection Program
Biopharmaceuticals
 HSMN NewsFeed - 16 Aug 2006
The New England Journal of Medicine Publishes Results of Cubist's Landmark Study of Staphylococcus Aureus Blood Stream Infections
Biopharmaceuticals
 HSMN NewsFeed - 2 Aug 2006
Cerexa Reports Positive Top-Line Results for Phase 2 Clinical Trial of Ceftaroline
Biopharmaceuticals
 HSMN NewsFeed - 25 Jul 2006
Study Shows Once-Daily AVELOX(R) as Effective as Multi-Dose Combination Therapy in Treating Complicated Intra-Abdominal Infections
Biopharmaceuticals
 HSMN NewsFeed - 18 Jul 2006
Theravance and Astellas Add Japan to Collaboration on Telavancin, Investigational Antibiotic for Serious Infections
Biopharmaceuticals
 HSMN NewsFeed - 16 May 2006
Theravance Announces Enrollment of Last Patient in Phase 3 Complicated Skin and Skin Structure Infections Clinical Program With Investigational Antibiotic, Telavancin
Biopharmaceuticals
 HSMN NewsFeed - 7 Apr 2006
AVELOX(R) Monotherapy as Effective as High-Dose Levofloxacin and Ceftriaxone Combination Therapy in Treating Patients With Severe Community-Acquired Pneumonia
Biopharmaceuticals
 HSMN NewsFeed - 24 Mar 2006
FDA Issues Approvable Letter for CUBICIN sNDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Mar 2006
FDA Grants Cerexa Fast Track Designation for PPI-0903
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Mar 2006
Wyeth Pharmaceuticals' Antibiotic TYGACIL Receives 'Positive Opinion' From European Regulatory Authority
Biopharmaceuticals Regulatory
Return to NewsFeed  

 Additional items found! 12

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 12 additional stories matching:
cSSSI
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.